National Organization for Rare Disorders, Inc.
It is possible that the main title of the report Galactosemia is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.
- Galactose-1-Phosphate Uridyl Transferase Deficiency
- GALT Deficiency
- Classic Galactosemia
- Galactokinase deficiency
- Galactose-6-phosphatase emirase deficiency
Related Disorders List
Information on the following diseases can be found in the Related Disorders section of this report:
- Lactose Intolerance, also known as Lactase Deficiency, Disaccharidase
- Deficiency, Glucose-Galactose Malabsorption, or Alactasia
Galactosemia is a rare, hereditary disorder of carbohydrate metabolism that affects the body's ability to convert galactose (a sugar contained in milk, including human mother's milk) to glucose (a different type of sugar). Galactose is converted to glucose by a series of three enzyme reactions. The disorder is caused by a deficiency of an enzyme known as "galactose-1-phosphate uridyl transferase" which is vital to this process.
Galactosemia may also be referred to as classic galactosemia because a few variants of the gene for galactosemia have been identified. One variant causes a milder form of the disorder known as Duarte galactosemia. Classic galactosemia is the most severe form.
Because milk is the staple of an infant's diet, early diagnosis and treatment of this disorder is absolutely essential to avoid serious lifelong disability.
An infant with galactosemia appears normal at birth, but within a few days or weeks loses his appetite (anorexia) and starts vomiting excessively. Yellowing of the skin, mucous membranes, and whites of the eyes (jaundice), enlargement of the liver (hepatomegaly), appearance of amino acids and protein in the urine, growth failure, and, ultimately, accumulation of fluid in the abdominal cavity (ascites) and other swelling (edema) may also occur. Diarrhea, irritability, lethargy and repeated bacterial infections may also be early signs of galactosemia. In time, wasting of body tissues, marked weakness, and extreme weight loss occur unless the infant is treated for the deficiency.
Children with galactosemia who have not received early treatment may show arrested physical and mental development and are particularly susceptible to cataracts in infancy or childhood. In severe cases, overwhelming infection can cause life-threatening complications, but mild cases present few symptoms and no serious impairment(s).
In order to avoid the consequences of galactosemia, which may include liver or kidney failure, brain damage and/or cataracts, infants must be treated promptly by removing galactose totally from the diet. Children treated with this special diet usually show satisfactory general health and growth. They can make reasonable, though often not optimal, intellectual progress. Speech and vision difficulties and some behavioral problems may occur. Ovarian impairment is not uncommon in girls with galactosemia because of an increase in the blood level of the hormone gonadotropin; males with galactosemia have also been identified who have an excessive level of gonadotropin (hypergonadotropinism).
The abovementioned complications associated with classic galactosemia have not occurred in individuals with Duarte galactosemia. Significant debate exists in the medical literature as to whether individuals with Duarte galactosemia need to maintain a special diet.
Galactosemia is an autosomal recessive hereditary disorder. The most severe form of the disorder is caused by a deficiency of the enzyme galactose-1- phosphate uridyl transferase. The milder form is caused by a deficiency of the enzyme galactokinase. These enzymes are needed for the breakdown of the milk sugar, galactose. Two different toxic products in galactosemic patients have been identified: galactitol (an alcoholic derivative of galactose) and galactose-1-phosphate (a salt of galactose). Galactitol accumulates in the lens of the eye where it causes lens swelling and protein precipitation and, subsequently, cataracts. Accumulations of galactose-1-phosphate cause the other symptoms.
Genetic diseases are determined by two genes, one received from the father and one from the mother. Recessive genetic disorders occur when an individual inherits the same abnormal gene for the same trait from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease, but usually will not show symptoms. The risk for two carrier parents to both pass the defective gene and, therefore, have an affected child is 25% with each pregnancy. The risk to have a child who is a carrier like the parents is 50% with each pregnancy. The chance for a child to receive normal genes from both parents and be genetically normal for that particular trait is 25%.
Investigators have determined that galactosemia occurs due to disruptions or changes (mutations) of the GALT gene located on the short arm of chromosome 9 (9p13). Chromosomes, which are present in the nucleus of human cells, carry the genetic information for each individual. Pairs of human chromosomes are numbered from 1 through 22, and an additional 23rd pair of sex chromosomes which include one X and one Y chromosome in males and two X chromosomes in females. Each chromosome has a short arm designated "p" and a long arm designated "q". Chromosomes are further sub-divided into many bands that are numbered. For example, "chromosome 9p13" refers to band 13 on the short arm of chromosome 9. The numbered bands specify the location of the thousands of genes that are present on each chromosome.
The abnormal accumulation of galactose in various organs of the body causes the symptoms and physical findings of galactosemia.
Galactosemia appears in about 1 in 35-60,000 live births, with as many males affected as females. The disorder has been reported in all ethnic groups. An increased frequency of galactosemia occurs in individuals of northern European ancestry.
Symptoms of the following disorders can be similar to those of galactosemia. Comparisons may be useful for a differential diagnosis:
Lactose intolerance (LI) is a metabolic disorder characterized by the inability to break down lactose, the predominant sugar found in milk and milk products. People with LI cannot properly digest lactose because they lack or are deficient in the enzyme lactase which is key to the digestion of lactose. Lactose is a complex sugar made up of two different sugar molecules (disaccharide), galactose and glucose, each of which is a simple (monosaccharide) sugar and more readily absorbed in the body's stomach and intestine and processed in other organs. Individuals with a deficiency of lactase experience cramps, nausea, bloating, stomach rumbling (Borborygmi), gas (flatus) and/or diarrhea after eating or drinking lactose-rich foods, not all of which are dairy products. Symptoms are more severe when they occur in a newborn. The signs of congenital lactose intolerance are apparent soon after birth and usually include severe diarrhea, vomiting, abnormally low levels of body fluids (dehydration), and failure to thrive. Some infants may also have liver and kidney impairment. (For more information on this disorder, choose "lactose intolerance" as your search term in the Rare Disease Database.)
Neonatal hepatitis refers to a group of liver disorders that affect newborns between the ages of about 1 and 2 months, and produce a typical yellow color to the infant's skin (jaundice). Most, but by no means all, cases of neonatal hepatitis can be traced to rare, inherited errors of metabolism or to prenatal infection by one or another of the hepatitis viruses. Many cases, however, seem to occur for no apparent reason (sporadic) and, in rare instances, neonatal hepatitis may be inherited as an autosomal recessive genetic trait. The symptoms of neonatal hepatitis are usually apparent 2 to 4 weeks after birth. Symptoms may include an abnormal yellow discoloration of the skin and/or eyes (jaundice), pale stools, unusually dark urine, and/or abnormal enlargement of the liver (hepatomegaly). By the age of 2 to 3 months, it becomes clear that an infant with neonatal hepatitis is not gaining weight and is growing at a slower than normal rate (failure to thrive). The infant may be irritable because of excessively itchy skin (pruritus). Other symptoms may include abnormal enlargement of the spleen (splenomegaly) as well as the blood vessels that surround the liver (hepatic collaterals), and/or the abnormal accumulation of body fluids within the abdomen (ascites). (For more information on this disorder, choose "neonatal hepatitis" as your search term in the Rare Disease Database.)
Pregnant women who are carriers for galactosemia (without symptoms) can be detected by testing for the activity of the enzyme "galactose-1-phosphate uridyl transferase" in their red blood cells. If the enzyme activity is 50% of the normal value, the individual is a carrier.
Infants at risk for galactosemia can and should be diagnosed at birth (or earlier) by testing for enzyme activity levels in red blood cells, using a drop of blood from the umbilical cord.
Children with galactosemia should have a diet that contains lactose-free milk substitutes and other foods such as casein hydrolysates and soy bean products. Strict dietary restriction should be maintained until the child is at least 2 years old or preferably 6 years. A lactose tolerance test should NOT be administered to galactosemic children. Fortunately the body of an infant with galactosemia can synthesize galactolipids and other essential galactose-containing compounds without the presence of galactose in food. Therefore, satisfactory physical development is possible if a strict diet is followed.
Appropriate treatment (i.e., antibiotic drugs) may be necessary to control infection. The emotional effects of the strict diet may require attention and supportive measures throughout childhood. Genetic counseling is recommended for families with children who have galactosemia.
Research is continuing into the use of the drug ureline as a possible treatment for galactosemia. More study is needed to determine the long-term safety and effectiveness of the use of this drug. For more information on this study, contact:
Francine Kaufman, M.D.
Children's Hospital of Los Angeles
4650 Sunset Blvd.
Los Angeles, CA 90027
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
Berry GT. Galactosemia. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:446.
Larson, D.E., Editor-in-Chief, Mayo Clinic Family Health Book. 2nd ed., New York, NY: William Morrow and Company, Inc; 1996:8.
Beers MH and Berkow R., eds. The Merck Manual. 17th ed., Whitehorse Station, NJ: Merck Research Laboratories; 1999:2386-87.
Segal S. Galactosemia. In: Bennett JC., Plum F. Cecil Textbook of Medicine. 20th ed. Philadelphia, PA: W.B. Saunders Company; 1996:1080-82.
Nelson Textbook of Pediatrics. 16th ed. W.B. Saunders; 2000
Leslie ND. Insights into the pathogenesis of galactosemia. Annu Rev Nutr. 2003;23:59-80.
Elsas LJ, et al. Functional analysis of the human galactose-1-phosphate uridyltransferase promoter in Duarte and LA variant galactosemia. Mol Genet Metab. 2001;72:297-305.
Shinka T, et al. Urine screening of five-day-old newborns: metabolic profiling of neonatal galactosuria. J Chromotogr B Biomed Sci App. 1999;732:469-77.
Tyfield L, et al. Classical galactosemia and mutations at the galactose-1-phosphate uridyl transferase (GALT) gene. Hum Mutat. 1999;13:417-30.
Shin YS, et al. Molecular and biochemical basis for variants and deficiency form of galactose-1-phosphate uridyltransferase. J Inherit Metab Dis. 1999;22:327-29.
Walter JH, et al. Generalised uridine diphosphate galactose-4-epimerase deficiency. Arch Dis Child. 1999;80:374-76.
Langley SD, et al. Molecular basis for Duarte and Los Angeles variant galactosemia. Am J Hum Genet. 1997;60:366-72.
FROM THE INTERNET
Adult metabolic transition program. University of Washington website. Available at: http://www.uwmedicine.org/.
CLIMB (Children Living with Inherited Metabolic Diseases)
176 Nantwich Road
Crewe, CW2 6BG
American Liver Foundation
39 Broadway, Suite 2700
New York, NY 10006
P.O. Box 2401
Mandeville, LA 70471
NIH/National Institute of Diabetes, Digestive & Kidney Diseases
Office of Communications & Public Liaison
Bldg 31, Rm 9A06
31 Center Drive, MSC 2560
Bethesda, MD 20892-2560
Galactosaemia Support Group
31 Cotysmore Road
West Midlands, B75 6BJ
Cochrane Cystic Fibrosis and Genetic Disorders Group
Institute of Child Health, University of Liverpool
Alder Hey Children's NHS Foundation Trust
Liverpool, L12 2 AP
PO Box 241956
Los Angeles, CA 90024
Canadian Families with Galactosemia
5 Bayview Ave.
Ontario, L9H 4W8
For a Complete Report
This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.
The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only. NORD recommends that affected individuals seek the advice or counsel of their own personal physicians.
It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report
This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.
For additional information and assistance about rare disorders, please contact the National Organization for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site www.rarediseases.org or email firstname.lastname@example.org
Last Updated: 7/23/2007
Copyright 1987, 1990, 1991, 1995, 1999, 2005, 2007 National Organization for Rare Disorders, Inc.
Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.